This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Kidney failure occurs when a person's kidneys can no longer make enough urine to remove enough waste products and fluid from the blood to keep that person alive. People with kidney failure need treatments to filter their blood to stay alive. Treatments that filter the blood are called dialysis. People with kidney failure can also be given a kidney from another people, and that new kidney can filter their blood and keep them alive. This is called a kidney transplant. There are problems associated with dialysis. Dialysis is expensive, time consuming, and requires procedures that may have complications such as infection or bleeding. Also, dialysis cannot substitute entirely for a working kidney, and so it does not remove all the toxins and fluid from a person's body that a working kidney does. This means that people on dialysis must be extremely careful about what they eat and drink. The usual diet that is recommended is very restrictive and people often have trouble following it. There are also problems associated with kidney transplants. It is difficult to get a kidney transplant because the number of kidneys available is much smaller than the number of people with ESRD who need a kidney transplant. People who receive a kidney transplant must take medicines that suppress their immune systems to prevent their bodies from rejecting the kidney transplant. These medicines increase people's risk for life-threatening infections and cancer. The purpose of this study is to learn about a compound called cross-linked polyelectrolyte, or CLP. CLP is a new substance that researchers from the company DOW have invented. CLP is a substance that people can swallow, that then travels through the intestines. While CLP is traveling through the intestines, it can soak up water, salt, and waste products. CLP is then leaves a person's body in their stool. Researchers do not know how safe CLP is. Researchers also do not know if CLP has any serious side effects. CLP has already been given to fourteen people with kidney failure. The results were encouraging, and researchers would like to learn more about CLP. The main reason for this study is to learn whether CLP is safe in people with kidney failure. Another reason for this study is to learn how people feel while they are taking CLP. Researchers also want to do this study to learn how well CLP soaks up water, salt, and waste products from the intestines. It is possible that CLP may help people with kidney failure follow a less restrictive diet. CLP may help delay the need for dialysis or for a kidney transplant for some people with kidney failure. It is possible that some people who need hemodialysis treatments three times a week could substitute CLP for one of their treatments. If this study goes well, researchers plan to use information from this study to plan another larger study, in which more people with kidney failure will be given CLP, to see if CLP can help them.'

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000042-47
Application #
7603772
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2007-03-01
Project End
2007-09-16
Budget Start
2007-03-01
Budget End
2007-09-16
Support Year
47
Fiscal Year
2007
Total Cost
$35,249
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Spengler, Erin K; Kleiner, David E; Fontana, Robert J (2017) Vemurafenib-induced granulomatous hepatitis. Hepatology 65:745-748
Heidemann, Lauren; Law, James; Fontana, Robert J (2017) A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci 62:615-625
Law, Ian H; Alam, Osman; Bove, Edward L et al. (2016) Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation. Circ Arrhythm Electrophysiol 9:
Schrepf, Andrew; Harper, Daniel E; Harte, Steven E et al. (2016) Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain 157:2217-2225
As-Sanie, Sawsan; Kim, Jieun; Schmidt-Wilcke, Tobias et al. (2016) Functional Connectivity is Associated With Altered Brain Chemistry in Women With Endometriosis-Associated Chronic Pelvic Pain. J Pain 17:1-13

Showing the most recent 10 out of 1380 publications